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drugs across ATC groups appeared to differ between the EMA and FDA suggesting 
the regulatory bodies may have different preferences with regard to research and 
development in the various therapeutic fields.
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BAckground: In Russia all drugs for state medical organisations and programs 
are purchased through public tenders in order to enhance competition, decrease 
price and prevent corruption. Drugs for rare diseases (DRD) are often produced by 
the only manufacturer thus being monopolistic. There is lack of information about 
the effectiveness of tender procedures for DRD in real life. oBjectives: To assess 
the competition in public procurement of DRD and effectiveness of tender proce-
dures. Methods: The analysis was conducted on the basis of 1499 selected trade 
procedures on DRD procurement in 2013. We evaluated the proportion of procedures 
that have passed with the only one participant, the level of price reduction resulted 
from trading, the amount and volume of purchases of DRD in the subjects of the 
Russian Federation. Data on drug procurement procedures were obtained from the 
official website of state purchases www.zakupki.gov.ru. Data collection and process-
ing were performed using the program Microsoft EXCEL and Statistica 6.1. results: 
Total amount of spending for DRD in 2013 was € 192.23 million, with declared pro-
cedures on € 197.93 million. Competition was absent in 592 (74.47%) procedures of 
monopolistic drugs procurement. 75% of tenders were performed without reduc-
ing the price. There were € 5.69 million savings generated by purchases (3% of the 
amount of declared procedures). conclusions: Tender procedures used for the 
procurement of monopoly drugs are ineffective because of the lack of competition; 
distributors are not interested in price reduction at noncompetitive procedures.
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oBjectives: The objective of this study is to analyze and compare the recom-
mendation made by several countries for orphan drugs such as Canada, Scotland, 
Australia, France and England.The study will try to address solutions and innovative 
ways to evaluate orphan drugs from an economic perspective and try to propose 
the hallmarks of an ideal policy to be implemented. Methods: The Orphanet 
website was screened to find orphan drugs with national designations.237 orphan 
drugs indication were retrieved and 36 technologies were included in the study and 
stratified by therapeutic areas.In total, 180 recommendations were analyzed for the 
5 included HTA agencies. Each recommendation was analyzed for the following 
parameters: Listing, clinical recommendation, economic recommendation, QALYs 
and rarity of disease taken in consideration. results: Scotland (88%) was the coun-
try that took the most in consideration the orphan designation of drugs, followed by 
France (74%) and Australia (45%). In addition, France and Scotland were the 2 coun-
tries that had the most positive listings (with criteria or without). The clinical benefit 
was demonstrated in multiple drugs throughout the different agencies. However, the 
economic part was very heterogeneous. Scotland issued a lot of positive economic 
recommendations (60%); however countries such as Canada had a very low percent-
age of economic being accepted (19%). QALYs did not seem to correlate with the type 
of listing.Countries that had the most health policies regarding orphan drugs had 
a better rate of orphan drugs being accepted for reimbursement. conclusions: 
Though there are certain similarities across countries with regards to the HTA of 
orphan drugs, significant differences exist, which are likely to continue to cause 
variations in access to orphan drugs across countries. Positive listing by CADTH was 
one of the lowest between 5 countries and the economic recommendations were 
the most negative in Canada.Seperate funding for orphan drugs and specific clinical 
assessment should idealy be implemented throughout the world.
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oBjectives: Since the introduction of the European rare diseases policy in 2000, 82 
drugs have received orphan status. As the orphan drug market is rapidly expanding, 
this number is expected to increase. The research objective was to identify how 
European countries manage the increase in available orphan drugs and whether 
there are similarities or differences in orphan drug reimbursement policies across 
Europe. Methods: We assessed orphan drug policies in 16 European countries, 
grouped into four archetypes: health insurance markets (Austria, Belgium, France, 
Germany, The Netherlands, Switzerland); devolved markets (Italy, Spain); health eco-
nomic markets (Ireland, Portugal, UK); Nordic country markets (Denmark, Norway, 
Sweden). Policies were assessed considering five key factors: key stakeholders; 
treatment setting; evidence requirements; reimbursement processes; source of 
funding. results: In all country archetypes, except Nordic markets, the reimburse-
ment assessment of orphan drugs used for in- and out-patient care is the same. 
All archetypes, except health insurance markets, follow the same processes for 
orphan and non-orphan drugs. Although in Scotland and England, drugs classified 
as ultra-orphan go through specialised processes. In devolved markets, economic 
and clinical data are considered; in health insurance markets, economic data are 
only considered under certain circumstances in some countries. Nordic countries 
have fewer evidence requirements than other archetypes. In both health economic 
and health insurance markets, orphan drug funding varies with treatment setting. 
oBjectives: Anemia affects about 25% of the world population and is the second 
main cause of incapacity worldwide. Clinical guidelines recommend upfront use 
of iron (oral or intravenous, IV) to correct iron deficiency anemia (IDA) instead of 
blood transfusion (BT). Nonetheless, utilization of BT is a common practice fre-
quently associated with clinical complications and high economic burden. Our 
main objective was to estimate the impact of BT in hospital length of stay (LOS) 
and in intra- and extra-hospital mortality of patients with IDA. Methods: This 
was a non-interventional, retrospective, single-center study. A convenience sam-
ple composed of 196 IDA patients treated with IV iron during 2013 was analyzed. 
Data was retrieved from patients’ clinical and pharmacy records. Between-group 
comparisons were performed using non-parametric methods (Mann-Whitney-
Wilcoxon and Kruskal Wallis). Logistic regression models were estimated to assess 
the odds of intra-hospital mortality. Kaplan-Meier survival estimates and Peto test 
were used to assess survival after hospital discharge (extra-hospital mortality). A 
5% significance level was adopted. results: Here we present the results of the 
subset of 136 hospitalized patients, mean (SD) age of 68.6 (18.7) years and 50.7% 
males, corresponding to 148 hospitalization episodes. In 62.2% of these episodes 
at least 1BT was performed. Mean LOS was significantly higher in patients with 
BT (29.2 versus 15.3 days; p-value< 0.0001). The odds ratio of dying during hospi-
talization in patients with > 2BT was 3.73 (95%CI: 1.01-13.74) when compared to 
patients with ≤ 2BT, adjusting for age, sex, surgery or iron IV utilization. We observed 
a higher extra-hospital mortality in BT patients although not statistically significant 
(p-value= 0.118), probably due to the low number of patients with follow-up data 
(n= 33). conclusions: Blood transfusions result in higher hospital length of stay 
and mortality. A better patient blood-management may improve patient outcomes 
and provide a more efficient use of health resources.
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oBjectives: Current validated DAIs in SLE require disease expertise and/or 
involve complex scoring systems, and are often impractical for use in daily clini-
cal practice. To address this, several new simplified DAIs in SLE are in different 
stages of development, including SLE Activity Tracking Evaluation Tool (LAST:14 
items; includes medications, Physician Global Assessment (PhGA) 0-10 scale, Patient 
Global Assessment (PtGA:0-10), C3, C4 & anti-dsDNA lab measures), Clinical LAST 
(C-LAST:11 items; similar to LAST, without lab measures), Total Lupus Activity Score 
(TLAS:30 items; includes 15 physician clinical assessments and 15 patient self-
assessment of symptoms), and Simple Disease Assessment for People with Lupus 
Erythematosus (SIMPLE:17 items; includes patient self-assessment of symptoms, 
Lupus Impact Tracker, steroid medication, C3, C4 & proteinuria). The primary objec-
tive of this analysis is to assess the convergent validity of these various tools as 
well as PhGA indices in relation to SLEDAI-2K. Methods: This is a prospective real-
world observational cohort study of SLE patients receiving standard care in 2 private 
and 2 academic sites in the US. Respective portions of DAIs are completed by physi-
cians and patients at four timepoints: baseline/3mo/6mo/12mo. DAI completions: 
SLEDAI-2K:201; TLAS/SIMPLE: approx. 152; LAST/C-LAST:168. Pearson correlation 
coefficient (r) was computed comparing mean SLEDAI-2K score to other DAI scores 
at baseline. results: 201 SLE patients were enrolled (mean age:45yrs; female:91%; 
Black/African-American (AA):56%; Hispanic:10%). At baseline, mean SLEDAI-2K score 
was 3.4 (SD:3.2); each of the DAIs had statistically significant positive correlation 
with the SLEDAI-2K: LAST (r= 0.566/p< 0.0001), PhGA:0-10 scale (r= 0.563/p< 0.0001), 
SIMPLE (r= 0.560/p< 0.0001), PhGA:0-3 scale (r= 0.553/p< 0.0001), C-LAST (r= 0.450/
p< 0.0001) and TLAS (r= 0.348/p< 0.0001). Analysis stratified by AA and non-AA sta-
tus revealed similarly significant correlations between SLEDAI-2K and the other 
DAIs. conclusions: In this cross-sectional analysis, each of the studied DAIs 
appeared to have convergent validity with the SLEDAI-2K. Further analyses with 
longitudinal data will assess additional psychometric properties of the instruments.
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oBjectives: Developing innovative treatments for rare diseases is intrinsically 
difficult due to small patient population sizes and the scarcity of high quality evi-
dence. Orphan drug designation is attributed to drugs which have been developed 
to treat rare diseases; however, the European Medicines Agency (EMA) and US Food 
and Drug Administration (FDA) define rare diseases differently. The objective of this 
study was therefore to investigate the number and type of orphan drug designations 
across the EMA and FDA. Methods: Data on authorised drugs awarded orphan 
status by the EMA and FDA is freely available and was obtained from their respec-
tive websites. Authorised orphan drugs were analysed dating back to the first EMA 
orphan drug designation in 2002. results: The EMA designated 82 drugs orphan 
status, whilst the FDA designated 170 drugs orphan status. An upward trend in 
the number of drugs designated orphan status by the EMA was observed, whilst 
a downward trend was present in FDA orphan designations. The distribution of 
orphan drugs across WHO Anatomical Therapeutic Chemical (ATC) classifications 
appears to vary, for instance: 18% of EMA authorised orphan drugs were in the 
alimentary tract and metabolism group (ATC code A), compared to just 6% of FDA 
orphan drugs. Conversely, orphan drugs in the blood and blood forming organs 
category (ATC code B) comprised 2% of EMA authorised orphan drugs compared 
to 12% with the FDA. conclusions: The EMA has designated half the number of 
drugs orphan status compared to the FDA however the number of authorised drugs 
designated orphan status appears to be on the rise in Europe. The pattern of orphan 
